Trial Profile
A retrospective, observational study assessing the persistence to biologic therapy among patients with Spondyloarthritis using the OPAL Dataset
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Aug 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Rituximab (Primary) ; Secukinumab (Primary) ; Tocilizumab (Primary) ; Tofacitinib (Primary) ; Ustekinumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
Most Recent Events
- 09 Aug 2021 New trial record
- 01 Aug 2021 Results published in The Journal of Rheumatology